Clinical management of pheochromocytoma and paraganglioma in Singapore: missed opportunities for genetic testing

Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors of the adrenal glands and paraganglia, occurring sporadically or as a range of hereditary tumor syndromes. About 30% of PPGLs are attributed to germline mutations. Clinical presentation, including localization, malignant potential, and age of onset, varies depending on the genetic background. Genetic testing for PPGLs is not well studied in Southeast Asia. We reviewed clinical management of PPGLs in Singapore, highlighting current gaps in clinical practice.

[1]  N. Shah,et al.  Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience , 2016, Endocrine connections.

[2]  K. Soo,et al.  Impact of subsidies on cancer genetic testing uptake in Singapore , 2016, Journal of Medical Genetics.

[3]  A. Gimenez-Roqueplo,et al.  Paraganglioma and phaeochromocytoma: from genetics to personalized medicine , 2015, Nature Reviews Endocrinology.

[4]  R. Bennett,et al.  A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment , 2014, Genetics in Medicine.

[5]  A. Mojtahedi,et al.  The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. , 2014, American journal of nuclear medicine and molecular imaging.

[6]  W. Young,et al.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[7]  P. Dahia.  Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity , 2014, Nature Reviews Cancer.

[8]  M. Fassnacht,et al.  Long-term Postoperative Follow-up in Patients with Apparently Benign Pheochromocytoma and Paraganglioma , 2012, Hormone and Metabolic Research.

[9]  P. Söderkvist,et al.  Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. , 2011, Endocrine-related cancer.

[10]  Fiona Douglas,et al.  Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD , 2010, Human mutation.

[11]  G. Arnaldi,et al.  Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. , 2009, The Journal of clinical endocrinology and metabolism.

[12]  E. Baudin,et al.  Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.

[13]  H. Lehnert,et al.  Phaeochromocytoma, new genes and screening strategies , 2006, Clinical endocrinology.

[14]  W. Manger.  An Overview of Pheochromocytoma , 2006, Annals of the New York Academy of Sciences.

[15]  K. Byth,et al.  Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.

[16]  S. Richard,et al.  Genetic testing in pheochromocytoma or functional paraganglioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  David I. Smith,et al.  Malignant pheochromocytoma: current status and initiatives for future progress. , 2004, Endocrine-related cancer.

[18]  J. Strauchen.  Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[19]  N. Abumrad,et al.  Clinical experience over 48 years with pheochromocytoma. , 1999, Annals of surgery.